Skip to main content
BIO CEO & Investor Conference Logo
Show Dates

  March 2-3, 2026・Miami, FL

BIO CEO & Investor Conference Logo
Show Dates

  March 2-3, 2026・Miami, FL

2025 Program

blue gradient

Loading
  1. Advanced Business Development-Day 1 of 3
    • Oncology
    • Non-Profit/Patient Advocacy Group
    This is a three day course requiring attendance on all three days. "Advanced Business Development "(ABD) is a long-running course focusing on all key aspects of transactions in the biopharma industry. ...
  2. Translating Nobel Prize science into the clinic
  3. Copays Kill: How Cost Sharing Undermines Health
  4. Rescuing Promising but Shelved Assets: New Models to Overcome Barriers and Put Unmet Patient Needs First
  5. 35th Biotech Beyond Borders Report: Are Capital Markets Finally Coming Back?
  6. Next-Gen Advocates: Patients & Families Driving Breakthroughs in Rare Disease Drug Development
  7. AI in biologics drug discovery: analyzing the competitive landscape, technical approaches, and the industry's role.
  8. Novel Oncology Targets & Modalities Enter the Clinic - What’s Next?
  9. Fueling Innovation: Strategies for Funding Academic Spin Outs
  10. Foundation Models for Genomics: Current Advances and Future Directions
  11. Trusting the Machines: Designing Transparent AI Solutions for Healthcare
  12. Achieving Synergy: A Roadmap to Successful Academia-Industry Collaborations from Discussion to Implementation
  13. “Journey Into the [Un]validated” – a practical guide to partnering early with pharma on novel drug modalities!
  14. The Priority Review Voucher Program: Incentivizing Neglected Disease Research and Promoting Biotech Investment and Development for More than a Decade
  15. The New Era of Project Optimus: Implications for Oncology Development Strategy
  16. Advanced Business Development
  17. We’ve Entered a New Era of Neuropsychiatry: Precision in Practice
  18. Patient Diversity and Access to New Medicines – Can AI improve access in disadvantaged patient populations and optimize the economics of medical innovation?
  19. Flow of Capital to Women's Health : from innovation to patient
  20. What are the opportunities and challenges for the new generation of TechBio partnerships powered by Generative and Foundational AI?
  21. US Legal and Regulatory Framework, Challenges, and Opportunities for AI Use in Pharma Product Development
  22. From Discovery to Deals: Bridging the Valley-of-Death with a Molecule-to-Medicine Expressway
  23. The Innovation Race vs. Regulatory Pace: What to do when innovation outpaces regulation
  24. Oncology investment themes: where is the market putting its money?
  25. Undermining Innovation: How antimicrobial resistance imperils patients and threatens the future of medicine
  26. Best Practice for Genuine Sustainability- Pharmaceutical Companies in Latin America are Implementing Successful Sustainable Practices Without Resorting to Greenwashing.
  27. Shifting Attitudes Toward Vaccines Among Lawmakers
  28. Commercializing SBIR/STTR Technologies
  29. Expanding the reach of Cell Therapies: Shaping the Future of Autoimmune Disease Treatment
  30. Celebrating Women Leading Innovation in Biopharma
  31. Biotech M&A 2025: What’s Driving Deal Making in The New Environment
  32. Business Development Fundamentals
  33. Navigating regulations to bring cell/gene therapies to patients in Europe and Middle East
  34. Become a Biotech or MedTech Entrepreneur
  35. The Role of Small Investors in the Biotech Funding Landscape – a global perspective
  36. Guide to Raising Institutional Private Capital
  37. Trends in Dealmaking: Shaping Drug Development Through External Innovation
  38. Product & Company Valuation
  39. Commercialization Readiness From Preclinical to 1st Launch: The First Time CEOs Playbook
  40. Program Committee
  41. Master the Art of Business Development Negotiations
  42. Ethical and Practical Considerations for Multi-National Rare Disease Clinical Trials
  43. Optimizing Clinical Trial Design and Execution for Rare Diseases
  44. Policy Outlook: All Eyes on Intellectual Property Rights
  45. Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
  46. Platform Licensing: Biotech and Pharma Perspectives
  47. Leveraging the Accelerated Approval Pathway for Rare Diseases
  48. Profit and Access: Groundbreaking Strategies to Make Medicines Available in Resource-Challenged Markets
  49. Companies should embrace RWE strategies early and often to enhance shareholder and stakeholder value throughout drug development and commercialization
  50. Fuel Your Innovative Cancer Breakthrough: From Unlocking Dilutive and Non-Dilutive Funding to Fostering Fruitful Partnerships
  51. Rapid response capabilities of global health and biosecurity countermeasures during outbreaks- leveraging public private partnerships.
  52. How to Best Scale CGT Manufacturing: Bringing Together Disparate Approaches
  53. It’s not “Just the Flu”: Harnessing innovation to save lives
  54. Platform Power: How Genetic Medicine Technologies Are Changing Expectations for Medicine
  55. The New Era of Mega Blockbusters: Advancing Drug Development for Broader Patient Impact
  56. Examining innovative business models for creating sustainable network and capabilities for public health and biosecurity countermeasures
  57. The “RNAissance” Era – Recent Breakthroughs, Future Prospects, and Challenges of RNA Therapeutics
  58. Co-Discovery and Co-Development Partnerships to Accelerate Next-Generation Medicines
  59. In Vivo CARs: Unlocking the Potential of Immune Cell Programming in Oncology and Beyond
  60. European biotech: Unlocking investment opportunities
  61. Weight Loss for Longevity? How metabolic drugs are disrupting chronic disease and improving healthspan
  62. INTELLECTUAL PROPERTY CONSIDERATIONS FOR INVENTIONS MADE BY, OR INVOLVING, ARTIFICIAL INTELLIGENCE
  63. Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and Bottlenecks
  64. “What If?” Preparing for Cybersecurity Risks Begins by Understanding AI’s Role in Attacks and Defense
  65. Scalable Biomanufacturing for Living Medicines: Pioneering the Future Today
  66. Understanding and Mitigating the Consequences of Loper Bright, Corner Post & Judicial Activities on Drug Development, Commercialization, and Investment
  67. AI in Biopharma: What’s Working and What’s left to prove
  68. Integrating AI-Driven Drug Discovery to Improve R&D Supply Chain Efficiency
  69. Accelerated Approval and Patient Need: The Value of Earlier Access
  70. Bridging the Innovation Valley of Death – a Call for Greater Pharma-Biotech-Academia Collaboration
  71. Healthcare AI Opportunities and Headwinds at NIH and the Ecosystem at Large: Fulfilling the Promise or Machine Learning Impaired?
  72. Preparing for the next generation in antimicrobial resistance: Combining traditional with non-traditional therapeutic approaches to tackle an ongoing pandemic
  73. We Still Need the People: AI/ML Drug Discovery is Here to Stay, but we Could be its Rate Limiting Factor
  74. In Pursuit of Health Equity: How Industry Has Evolved Its Focus On This Critical Healthcare Challenge
  75. Evolving from Patient Centricity to Integrated Patient Engagement- Change Management Experience and Key Learnings
  76. CI for the Biotech Journey: Applying Lessons from Pharma
  77. Advancing innovative risk-stratification tests that impact treatment pathway decisions: challenges in overcoming barriers to entry
  78. Beyond the Contract: Building Successful Biotech Partnerships
  79. Test Session
  80. Revolutionizing Drug Development: Harnessing New Approach Methodologies (NAMs) for a Safer Future in Medicine
  81. Beyond Innovation: Supercharging America's Biomanufacturing Infrastructure
  82. Building a Diverse Life Science Workforce for the Nation’s Bioeconomy: 4 industry-academic models
  83. Building and sustaining a comprehensive education and workforce development continuum to support an evolving industry: Massachusetts shares its lessons
  84. Bridging the biodata gap: Revolutionizing AI's impacts in biopharma by creating ‘digital twins’ of the natural world
  85. Weighing in on Weight Loss Medicine
  86. Innovative Patient-Focused Models for Accelerating Rare Drug Development
  87. An Eye on I&I: Innovations Fueling Growth
  88. Closing the practice gaps in precision oncology – what are the practical solutions?
  89. Global Puzzle: Decoding Cell Therapy Classifications in Europe and the USA
  90. Funding Workforce Diversity in Biomedical Innovation.
  91. Inflation Reduction Act (IRA) Litigation: Past and Future Impact on the Price Negotiation Framework
  92. Shaping Sustainability Strategies for Lasting Value
  93. Psychedelics Are Going Mainstream. Are you ready for it?
  94. Recognizing the “Why?” Behind Our Medicines: Patient Connection as a Motivator for Impact
  95. Expediting Impact: Leveraging the Patient Voice for Enhanced Clinical Trial Design and Accelerated Regulatory Approvals
  96. Overcoming Economic Challenges to Rare Disease Drug Development
  97. Attacking Cancer from All Angles: From ADCs to Immunotherapy
  98. Patient-reported Outcomes are Front and Center for Drug Development AND with the FDA and the CDC
  99. How VCs Evaluate Risk in Early Stage Startups
  100. Investors’ Perspectives – AI and Digital Health Investment Trends in 2025
  101. Carving out your ground in Immunology & Inflammation (I&I)
  102. Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?
  103. Effective Use of the New European Patent System as Part of your Global Patent Strategy
  104. From Skepticism to Opportunity: Building Investor Confidence in First-in-Class and First-in-Disease Drug Innovation
  105. Cracking the Code: Effective Biotech and Pharma Partnerships Unveiled
  106. Preparing for an IPO: Best Practices for Success
  107. Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug Discovery
  108. Who Are Today’s Biotech Underdogs and What It Will Take for Them to Succeed
  109. Next-Gen Medicine: How Gene Editing and Epigenetics are Revolutionizing Health, Longevity, and Organ Transplantation
  110. Next-Generation Alzheimer's Disease Therapies
  111. Physician and patient perspectives on the impact of the Inflationary Reduction Act on drug development, access, and innovation
  112. An Investor and a Value Assessor Walk into a Bar
  113. Unlocking the Future: Opportunities and Challenges in Advanced Biologics Manufacturing
  114. Improving and Restoring Vision in Blinding Eye Diseases
  115. Partnering with the U.S. Government to Achieve Our National Security Mission
  116. The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
  117. Affiliate Event Test
Testimonials
  • It's the kind of meeting where biotech newsmakers can have productive dialogs with investors and other key players.
    Luke Timmerman
    The Timmerman Report
  • It's the caliber of attendees - biopharma companies on the verge of their next big step and investors looking for smart opportunities - that make BIO CEO & Investor Conference vital to the industry.
    Anna Kazanchyan, MD
    Founder & CEO, Saghmos Therapeutics
  • The BIO CEO & Investor Conference offers a collaborative forum where executives, investors and industry stakeholders can come together to learn and exchange ideas about innovation in the biopharma ecosystem.
    Philip Ross, MD
    Global Chairman, J.P. Morgan Healthcare Investment Banking
  • The BIO CEO & Investor Conference provides timely and relevant content on the issues driving the business of biotech, along with an invaluable platform for networking and partnering.
    Chris Garabedian
    Chairman and CEO, Xontogeny and Portfolio Manager, PXV Fund

Double Helix

Loading

 

Supporting Bank Sponsor

Loading

 

Premier Sponsors

Loading

Conference Sponsors

Loading

 

Search